Ionis Pharmaceuticals

FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
Medical Marketing and Media
Biogen
Ionis Pharmaceuticals
ALS
tofersen
FDA
Flag link:
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Ionis, AstraZeneca's polyneuropathy med improved patients' quality of life in phase 3, teeing up battle with Alnylam
Fierce Biotech
Ionis Pharmaceuticals
AstraZeneca
eplontersen
Alnylam
ATTR
Flag link:
Could This Rare-Disease Drug Candidate Become a Blockbuster?
Could This Rare-Disease Drug Candidate Become a Blockbuster?
Motley Fool
AstraZeneca
Ionis Pharmaceuticals
eplontersen
ATTR amyloidosis
Flag link:
Go or no go? Seagen's Padcev eyes FDA approval
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
Flag link:
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
aplontersen
Alnylam
Onpattro
clinical trials
ATTRv-PN
Flag link:
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Investors Business Daily
Ionis Pharmaceuticals
Biogen
ALS
FDA
tofersen
Flag link:
Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm
Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm
BioSpace
ALS
Biogen
Ionis Pharmaceuticals
FDA
tofersen
clinical trials
Flag link:
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy
PR Newswire
Ionis Pharmaceuticals
FDA
eplontersen
hATTR-pn
Flag link:
Go or no go? Vaccines and neurology up for discussion
Go or no go? Vaccines and neurology up for discussion
EP Vantage
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
Flag link:
Biogen/ Ionis ALS therapy set for March FDA AdCom meeting
Biogen/ Ionis ALS therapy set for March FDA AdCom meeting
Seeking Alpha
Biogen
Ionis Pharmaceuticals
FDA
ALS
tofersen
Flag link:
JPM23: Ionis CEO admits PCSK9 ship captained by Big Pharmas may have sailed
JPM23: Ionis CEO admits PCSK9 ship captained by Big Pharmas may have sailed
Fierce Biotech
Ionis Pharmaceuticals
AstraZeneca
ION449
Flag link:
Ionis gets into gene editing
Ionis gets into gene editing
EP Vantage
Ionis Pharmaceuticals
gene editing
Metagenomi
Flag link:
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Ionis presents positive Phase 2 data from open label extension study of donidalorsen at 2022 ACAAI Annual Meeting
Yahoo Finance
Ionis Pharmaceuticals
clinical trials
donidalorsen
hereditary angiodema
HAE
Flag link:
As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data
As Roche prepares to take a kidney disease drug into PhIII, Ionis fleshes out the data
Endpoints
Roche
Ionis Pharmaceuticals
IONIS-FB-LRx
kidney disease
Flag link:
Ionis to build new manufacturing site in Southern California, doubling the size of its current site
Ionis to build new manufacturing site in Southern California, doubling the size of its current site
Endpoints
Ionis Pharmaceuticals
drug manufacturing
California
Flag link:
PCSK9 pipeline shows signs of saturation
PCSK9 pipeline shows signs of saturation
EP Vantage
AstraZeneca
ION449
Ionis Pharmaceuticals
Novartis
Leqvio
PCSK9 inhibitors
Flag link:
AstraZeneca dumps Ionis drug despite hit in phase 2 cholesterol trial
AstraZeneca dumps Ionis drug despite hit in phase 2 cholesterol trial
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
clinical trials
ION449
cholesterol
Flag link:
Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease
Data drip sheds little light on how Ionis, AstraZeneca compare to Alnylam in rare disease
Fierce Biotech
AstraZeneca
Ionis Pharmaceuticals
Alnylam
antisense
ATTRv-PN
aplontersen
Flag link:
Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant
Bayer-Ionis' anti-thrombotic med doesn't increase bleeding in phase 2, setting stage for a new type of anticoagulant
Fierce Biotech
Bayer
Ionis Pharmaceuticals
kidney disease
clinical trials
fesomersen
Flag link:
Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
Ionis announces enrollment completion of Phase 3 Lp(a) HORIZON cardiovascular outcomes study of pelacarsen
Yahoo Finance
Ionis Pharmaceuticals
clinical trials
cardiovascular disease
pelacarsen
Flag link:

Pages